Navigation Links
NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009
Date:9/13/2009

SAN DIEGO, Sept. 13 /PRNewswire/ -- NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA. The work was performed in collaboration with researchers at the Centers for Disease Control and Prevention (CDC), University of Hong Kong, and Saint Louis University.

DAS181 (Fludase(R)) is an investigational broad spectrum drug candidate being evaluated in human clinical development for treatment and prevention of Influenza-Like Illness caused by all strains of influenza and parainfluenza. Unlike neuraminidase inhibitors (NAI), e.g. Tamiflu(R), which directly target the influenza virus ("pathogen target"), DAS181 works by inactivating the human receptor ("host target") for these viruses; thus, it may be less likely to encounter acquired resistance compared with currently-available antiviral drugs. Extensive, prolonged nonclinical influenza studies have not shown the development of any meaningful resistance. This approach may have advantages over mono-therapy or combination therapy which directly target the pathogen. Previously announced preclinical studies conducted in collaboration with the CDC and others have shown DAS181 to have significant therapeutic and prophylactic activity in in vivo animal models and in human ex vivo lung tissue for a highly virulent H5N1 (A/VN/1203/04) strain of influenza.

A "Late Breaker" presentation, entitled "Novel Swine-Origin A (H1N1) Influenza Viruses are Potently Inhibited by DAS181, a Sialidase Fusion Protein" examined in vitro, ex vivo, and in vivo models to evaluate the activity of DAS181 against multiple human novel 2009 influenza A/H1N1 viruses (Novel H1N1 or "Swine Flu"). The data presented
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Sysmex America, Inc., ... information systems technology, will feature an exhibit booth during ... Meeting and Clinical Lab Expo in ... "We are extremely excited to exhibit ... to interact with our customers and continue the dialogue ...
(Date:7/29/2014)... , July 29, 2014 Apex Medical Corporation (Apex, ... Pressure Area Care sectors, announces that it is appealing the ... in Germany that found the ... notes that it has initiated invalidity challenges against various ResMed ... in counterattacking against trivial and junk patents. ...
(Date:7/29/2014)... July 29, 2014  Drug development for hepatitis ... incidence rates and the intense need for curative ... Change is underway as the market moves away ... effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first of ...
Breaking Medicine Technology:New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Apex Continues Fighting Against Patents to Free Up Competition 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
(Date:7/29/2014)... 2014 CHI-California Healthcare Institute today unveiled ... hepatitis C (hep C) epidemic in the U.S., the ... to reduce human suffering. The report examines key data ... hep C, while highlighting the significance of breakthroughs that ... CHI is a nonprofit, public policy research organization, representing ...
(Date:7/29/2014)... The Latin American poultry feed and feed additive ... forecast of revenue. The poultry feed and feed additive market ... and $647.2 million in 2013 to $34,024.0 million and $870.1 ... to 2018, respectively. , To get an idea of the ... the Latin American poultry feed and feed additive market report. ...
(Date:7/29/2014)... The Los Angeles based drug and ... a community program that helps homeless families in the ... the San Fernando Valley Rescue Mission to provide a ... Fernando Valley Rescue Mission offers emergency shelter and services ... Shelter provides housing and basic needs such as food ...
(Date:7/29/2014)... Frank Davis, Activz Founder and CEO, ... add nutrition to their kids’ meals in the ... drivers in kids’ foods market” by Kaylynn Chiarello-Ebner. , ... the interview Frank Davis had with Kaylynn Chiarello-Ebner, about ... and fruit produce powders to kids meals, was successfully ...
(Date:7/29/2014)... HealthDay Reporter MONDAY, July ... that continues to rage throughout West Africa poses little risk ... spreads through physical touch, and it can,t be spread by ... director of the National Center for Emerging & Zoonotic Infectious ... explained in a Monday afternoon news conference. Those factors ...
Breaking Medicine News(10 mins):Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 2Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 5Health News:The Discovery House Employees Volunteer at Local Rescue Mission 2Health News:The Discovery House Employees Volunteer at Local Rescue Mission 3Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:CDC Downplays Ebola's Threat to the United States 2Health News:CDC Downplays Ebola's Threat to the United States 3Health News:CDC Downplays Ebola's Threat to the United States 4
... each developed by Merck and Smith Glaxo Kline has found ... caused by the human papilloma viruses (HPVs). ... reduced infection in about 90% of the subjects. ... immunologic technologies have contributed to the discovery of the link ...
... revealed that having several older brothers increases the chances of ... //weight to the idea of a biological basis for sexual ... in St Catharines, Canada said, "It's likely to be a ... probably a biological basis for homosexuality." ,S Marc ...
... Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance ... a new oral drug option// to the group ... ,Celgene Corporation (Nasdaq: CELG) announced that the U.S. ... for its Supplemental New Drug Application (sNDA) for ...
... had stated on Friday that the precedent conditions of ... outbreak at Durban's Mahatma Gandhi Memorial Hospital, which had ... Mseleku said, “Nobody needs to communicate these problems. We ... It's (overcrowding and staff shortages) a known fact.” That ...
... by K M Shah Dental College an eye wash and ... admission //process by with a supposed entrance test held by ... for granting admissions. ,The court, had issued a ... admission should continue and has asked the Gujarat University (GU) ...
... Quebec say that chronic job stress can raise blood ... ,The research, appearing in the American Journal of ... deadlines increased blood pressure especially in men. The study ... study supports the hypothesis that job strain, particularly in ...
Cached Medicine News:Health News:Klebsiella Outbreak In Durban Blamed On Staff Shortage & Overcrowding 2Health News:Gujarat High Court Stays PG Admissions In A Private Dental Collage 2
... formula is the most convenient multi-purpose no ... one bottle without the need to rub: ... lenses and removes protein build-up when used ... contains Hydranate, a special ingredient that removes ...
Half Trial Frames with precision engineering and lightweight material....
Half Eye Trial Frame - Child...
Non Sterile surgical blade....
Medicine Products: